The FDA Vote & Peptide Sourcing
At the end of July, an FDA advisory committee recommended six of the seven peptides it reviewed for potential inclusion on the 503A Bulks List, the list that determines which bulk ingredients compounding pharmacies can work with. I already made a whole video breaking down the vote and my thoughts on it, so if you want the deeper version, you can watch it here: Why the FDA Peptide Vote Scares Me.
Here, I’m focusing on the part I’m probably most excited about: what this could eventually mean for peptide sourcing and access through licensed compounding pharmacies, and why that matters.
The Question I Get the Most
Sourcing is one of the peptide questions I get asked about the most, usually some version of this:
The compounding pharmacies and the research-use-only sites are all getting their peptides from China anyway. So what’s really the difference?
There’s definitely a kernel of truth in this. Most 503A compounding pharmacies in America aren’t synthesizing peptides from individual amino acids. Rather, they typically purchase peptides in bulk as API (active pharmaceutical ingredient), then compound the finished product, test it, and dispense it to individual patients. So yes, RUO sites and compounding pharmacies are likely both sourcing their API from overseas, typically China.
But that’s a lazy argument, because it glosses over what actually happens before a peptide vial gets to you. There are two points in particular where the process (and the accountability) splits.
Who Makes the API & Who Tests It
Not all API manufacturers are equal, and not every seller even touches the raw material. Plenty of RUO sites are essentially drop shippers: a vial arrives from overseas already made, and they just forward it to you. They never see the raw ingredient, so they never test or verify it. And even the RUO sites that do get raw material may be sourcing it from a lesser manufacturer, since they're unregulated and can pick the cheapest option that still clears a few limited test statistics.
A licensed compounding pharmacy, by contrast, is required to source from FDA-registered facilities and receive the actual raw ingredient, which means it can test what it's working with before anything moves forward.
Ask Your Source
Do you receive the API or the finished product? What testing is performed on the API, and at each step of the peptide creation process?
How the Peptide is Vialed
Sterile packaging is where the vial is actually made. Vialing may sound boring, but it’s worth caring about, because this is the step where other substances — microbes, endotoxins, and so on — are most likely to be introduced.
Based on my research, it’s rare for an RUO site to handle raw API at all. The ones that do rarely invest in the sterile lab equipment and procedures this step demands: it’s expensive, they’re already selling at a lower price point, and nothing requires it of them. Compounding pharmacies, on the other hand, are held to sterile compounding standards and pharmacy oversight, including inspections.
Ask Your Source
What sterile compounding standards is this made under, and how are they enforced?
One Honest Caveat
This isn’t to say compounding pharmacy equals good and RUO equals bad. It’s a spectrum, based on the quality of sourcing, testing, and sterile processes at each individual source. The best RUO site honestly might not be far off from the worst compounding pharmacy. But given the structural differences and the incentives on each side, the best RUO site likely still won’t match even an average compounding pharmacy.
KEY TAKEAWAY:
More access to the compounding pharmacy pathway means more people can choose a source with someone accountable at every point so you can feel confident in the peptide product you're receiving, instead of a site with limited obligations or accountability.